RefleXion’s Sam Mazin, Ph.D. Receives the University of Waterloo’s Faculty of Engineering 2021 Alumni Achievement Medal
December 10, 2021
HAYWARD, Calif., Dec. 9, 2021 – Samuel Mazin, Ph.D., founder and CTO of RefleXion Medical, has received the University of Waterloo’s Faculty of Engineering 2021 Alumni Achievement Medal for Professional Achievement in recognition of his innovative idea for biology-guided radiotherapy (BgRT*) for the treatment of cancer. The vision for BgRT is to expand treatment options for patients with all stages of cancer.
The Faculty of Engineering Alumni Achievement Medal program was established in 1994 to provide tangible recognition of alumni who have distinguished themselves through their professional achievements, community service or academic excellence.
“To be a recipient of this individual medal in recognition of professional achievement is truly a distinguished honor,” said Norbert J. Pelc, Sc.D., professor of Radiology, Emeritus at Stanford and Dr. Mazin’s Ph.D. and postdoctoral supervisor during his research tenure at Stanford. “Sam’s ability to take an idea he conceived, build a new company in an entrenched space and see it through to realization in the clinic is very impressive.
“I have watched Sam’s remarkable journey and application of his talents in the medical field from afar, and I am thrilled he is a recipient of this prestigious achievement award,” said En-Hui Yang, Ph.D., an Electrical and Computer Engineering professor at the University of Waterloo. “I was very impressed with Sam’s abilities and offered him a research assistantship in my lab. His impressive initiative combined with his keen academic interests in the field of how data and information can be used to better the world are attributes that enable him to contribute so much to the medical field.”
Dr. Mazin was recognized by the University of Waterloo as a recipient of the Engineering Alumni Achievement Medal in the Professional Achievement category during a virtual event held on December 8, 2021.
The breakthrough potential of BgRT lies in its ability to detect and then immediately treat moving tumors. It is the first and only technology to use injected radiotracers to produce active signals from each tumor to guide treatment delivery.
RefleXion is a privately held commercial stage company developing the first biology-guided radiotherapy system, a significant change in strategy from single tumor therapy to the ability to one day treat multiple tumors in the same treatment session in cancers that have metastasized. BgRT incorporates positron-emission tomography (PET) imaging data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with sub-second latency.
# # #
*The RefleXion® X1 is cleared for SBRT/SRS/IMRT. BgRT is limited by U.S. law to investigational use.